{
"info": {
"nct_id": "NCT03031691",
"official_title": "A Phase 1b Dose Escalation Study of the Safety and Pharmacodynamics of Brontictuzumab in Combination With Chemotherapy for Subjects With Previously Treated Metastatic Colorectal Cancer",
"inclusion_criteria": "* Histologically confirmed metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if KRAS wild-type, an anti-EGFR therapy\n* ECOG performance status 0 or 1\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
"exclusion_criteria": "* Prior treatment with gamma secretase inhibitors or other Notch 1 inhibitors\n* Subjects with known active HIV infection. Subjects with HIV that are under a stable anti-retroviral regimen and have no evidence of immune deficiency (normal CD4 counts), undetectable viral load, and no HIV-related infections are eligible\n* Subjects with uncontrolled diarrhea <30 days prior to first administration of study drug\n* Subjects with any history of or current clinically significant gastrointestinal disease including, but not limited to:\n\n * Inflammatory bowel disease (including ulcerative colitis and Crohn's disease)\n * Active peptic ulcer disease\n * Known intraluminal metastatic lesion(s) with risk of bleeding",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "* Histologically confirmed metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if KRAS wild-type, an anti-EGFR therapy",
"criterions": [
{
"exact_snippets": "Histologically confirmed metastatic colorectal cancer (mCRC)",
"criterion": "metastatic colorectal cancer",
"requirements": [
{
"requirement_type": "confirmation",
"expected_value": "histologically confirmed"
}
]
},
{
"exact_snippets": "previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy",
"criterion": "chemotherapy treatment",
"requirements": [
{
"requirement_type": "previous treatment",
"expected_value": [
"fluoropyrimidine-based",
"oxaliplatin-based",
"irinotecan-based"
]
}
]
},
{
"exact_snippets": "previously treated with ... an anti-VEGF biological therapy",
"criterion": "anti-VEGF biological therapy",
"requirements": [
{
"requirement_type": "previous treatment",
"expected_value": true
}
]
},
{
"exact_snippets": "if KRAS wild-type, an anti-EGFR therapy",
"criterion": "KRAS status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "wild-type"
}
]
},
{
"exact_snippets": "if KRAS wild-type, an anti-EGFR therapy",
"criterion": "anti-EGFR therapy",
"requirements": [
{
"requirement_type": "previous treatment",
"expected_value": true
}
]
}
]
},
{
"line": "* ECOG performance status 0 or 1",
"criterions": [
{
"exact_snippets": "ECOG performance status 0 or 1",
"criterion": "ECOG performance status",
"requirements": [
{
"requirement_type": "value",
"expected_value": [
"0",
"1"
]
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "healthy volunteers",
"requirements": [
{
"requirement_type": "allowed",
"expected_value": true
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "* Prior treatment with gamma secretase inhibitors or other Notch 1 inhibitors",
"criterions": [
{
"exact_snippets": "Prior treatment with gamma secretase inhibitors",
"criterion": "prior treatment",
"requirements": [
{
"requirement_type": "treatment type",
"expected_value": "gamma secretase inhibitors"
}
]
},
{
"exact_snippets": "Prior treatment with ... other Notch 1 inhibitors",
"criterion": "prior treatment",
"requirements": [
{
"requirement_type": "treatment type",
"expected_value": "other Notch 1 inhibitors"
}
]
}
]
},
{
"line": "* Subjects with known active HIV infection. Subjects with HIV that are under a stable anti-retroviral regimen and have no evidence of immune deficiency (normal CD4 counts), undetectable viral load, and no HIV-related infections are eligible",
"criterions": [
{
"exact_snippets": "known active HIV infection",
"criterion": "HIV infection",
"requirements": [
{
"requirement_type": "status",
"expected_value": "active"
}
]
},
{
"exact_snippets": "HIV that are under a stable anti-retroviral regimen",
"criterion": "anti-retroviral regimen",
"requirements": [
{
"requirement_type": "stability",
"expected_value": "stable"
}
]
},
{
"exact_snippets": "no evidence of immune deficiency (normal CD4 counts)",
"criterion": "immune deficiency",
"requirements": [
{
"requirement_type": "evidence",
"expected_value": false
}
]
},
{
"exact_snippets": "undetectable viral load",
"criterion": "viral load",
"requirements": [
{
"requirement_type": "detectability",
"expected_value": "undetectable"
}
]
},
{
"exact_snippets": "no HIV-related infections",
"criterion": "HIV-related infections",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* Subjects with uncontrolled diarrhea <30 days prior to first administration of study drug",
"criterions": [
{
"exact_snippets": "uncontrolled diarrhea <30 days prior to first administration of study drug",
"criterion": "uncontrolled diarrhea",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
},
{
"requirement_type": "time frame",
"expected_value": {
"operator": "<",
"value": 30,
"unit": "days"
}
}
]
}
]
},
{
"line": "* Subjects with any history of or current clinically significant gastrointestinal disease including, but not limited to:",
"criterions": [
{
"exact_snippets": "any history of or current clinically significant gastrointestinal disease",
"criterion": "gastrointestinal disease",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
},
{
"requirement_type": "current presence",
"expected_value": true
},
{
"requirement_type": "clinical significance",
"expected_value": true
}
]
}
]
},
{
"line": "* Inflammatory bowel disease (including ulcerative colitis and Crohn's disease)",
"criterions": [
{
"exact_snippets": "Inflammatory bowel disease (including ulcerative colitis and Crohn's disease)",
"criterion": "inflammatory bowel disease",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* Active peptic ulcer disease",
"criterions": [
{
"exact_snippets": "Active peptic ulcer disease",
"criterion": "peptic ulcer disease",
"requirements": [
{
"requirement_type": "status",
"expected_value": "active"
}
]
}
]
},
{
"line": "* Known intraluminal metastatic lesion(s) with risk of bleeding",
"criterions": [
{
"exact_snippets": "Known intraluminal metastatic lesion(s)",
"criterion": "intraluminal metastatic lesion(s)",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "risk of bleeding",
"criterion": "risk of bleeding",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}